RxDoctor Payments Data

Thaeer Sawa, MD

General Practice · Sterling Heights, MINPI 1093109241

Payments from drug & device makers

$3,450in general payments, 2019–2025

Across 57 payments — averaging $60.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$796
  • AstraZeneca$756
  • Lilly USA, LLC$748
  • Amarin Pharma, Inc.$265
  • Otsuka America Pharmaceutical, Inc.$227
  • Ardelyx, Inc.$125
  • plus $533 from 6 others

What the payments were for

  • Food & beverage$3,438100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,450 in reported general payments places this provider in the 95th percentile of 3,051 general practice providers in Michigan.

See all general practice providers in Michigan

Medicare billing

Part B allowed, 2024
$93,365
Medicare patients
84
Services billed
2,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin308$270,537
TrulicityDulaglutide149$149,459
LinzessLinaclotide235$125,999
EliquisApixaban108$81,685
ProliaDenosumab39$63,855
FarxigaDapagliflozin Propanediol79$59,819
TradjentaLinagliptin57$47,072
JanuviaSitagliptin Phosphate70$46,854
MounjaroTirzepatide30$32,470
EntrestoSacubitril/Valsartan25$27,984
VascepaIcosapent Ethyl88$21,931
MyrbetriqMirabegron43$18,766
SynjardyEmpagliflozin/Metformin Hcl19$18,044
Breo ElliptaFluticasone/Vilanterol31$13,736
OzempicSemaglutide12$13,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Spiriva Respimat$796$344,566401 claims
Lilly USA, LLCTrulicity, Mounjaro$748$181,929179 claims
PfizerEliquis$65$81,685108 claims
AmgenProlia$71$63,85539 claims
AstraZenecaFarxiga$756$59,81979 claims
MerckJanuvia, Janumet$89$58,19291 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,051 general practice providers in Michigan.

Other general practice in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →